Trial demonstrates early AI-guided detection of heart disease in routine practice
Related Articles
Anumana & Pfizer Partner on Amyloidosis AI-ECG Algorithm Development
HIT Consultant: Anumana, an AI-driven health technology company and portfolio company of nference, today announced a multi-year agreement with Pfizer for Anumana to develop an investigational artificial intelligence electrocardiogram algorithm…December 16, 2022
Anumana Acquires NeuTrace, Establishing a Comprehensive Electrophysiology Deep-Learning Development Platform and Product Pipeline
Anumana acquires NeuTrace, a medical technology company advancing novel in-procedure AI applications for electrophysiology (EP)November 07, 2022
Building sEHR-BERT: A Custom Language Model for Structured Electronic Health Records – Adapting transformer architecture for the unique challenges of medical coding and structured health data
Why Standard BERT Isn't Enough for Structured EHRs BERT revolutionized natural language processing, but electronic health records (EHRs) present unique challenges that standard language models weren't designed to handle. While BERT…January 22, 2026
Pfizer to partner with Mayo Clinic spinoff on early cardiac amyloidosis detection
Medtech Dive: Anumana, a health technology startup spun out of Mayo Clinic, entered a multi-year agreement with Pfizer to develop an algorithm to detect cardiac amyloidosis, a serious heart condition.…December 16, 2022